AARON E KATZ
Medical Practice at Long Pond Rd, Armonk, NY
License number
Florida 102128
Issued Date
Jun 26, 2008
Effective Date
Feb 18, 2016
Expiration Date
Jan 31, 2014
Category
Health Care
Type
Medical Doctor
Address
Address
38 Long Pond Rd, Armonk, NY 10504
Phone
(914) 282-2106
Organization information
See more information about AARON E KATZ at bizstanding.comAaron E Katz MD
38 Long Pond Rd, Armonk, NY 10504
Categories:
Urology Physicians & Surgeons
Phone:
(914) 273-5985 (Phone)
AARON E. KATZ, M.D., PC
38 Long Pond Rd, Armonk, NY 10504
Status:
Inactive
Inactive reason:
Dissolution by Proclamation / Annulment of Authority
Registration:
Jun 3, 1997
Inactive since:
Jan 27, 2010
State ID:
2149616
Business type:
DOMESTIC PROFESSIONAL CORPORATION
Md Aaron E Katz, 38 Long Pond, Armonk, NY 10504 (Physical)
Professional information
Method For Molecular Staging Of Prostate Cancer
US Patent:
5976794, Nov 2, 1999
Filed:
Jan 13, 1997
Appl. No.:
8/718547
Inventors:
Aaron E. Katz - Armonk NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C12Q 168, C12P 1934, C07H 2104
US Classification:
435 6
Abstract:
A method for enhancing the detection of prostate specific antigen in a biological sample comprising (a) extracting mRNA from the sample: (b) contacting the mRNA from step (a) with reverse transcriptase under conditions allowing for the production of cDNA; (c) contacting the cDNA from step (b) with a pair of reverse transcriptase polymerase chain reaction primers capable of specifically hybridizing with DNA encoding prostate specific antigen wherein one such primer is an oligonucleotide of 12 to 30 nucleotides in length and comprises the sequence 5-CACCCATCCTA-3' and wherein the second such primer is an oligonucleotide of 12 to 30 nucleotides in length and comprises the sequence 5'-TCCAGCCACGAC-3'; and wherein at least one of the primers is covalently linked to a modified digoxigenin molecule and under conditions allowing for extension of the primers; and (d) detecting the resulting amplified DNA.
Method For Molecular Staging Of Prostate Cancer
US Patent:
5840494, Nov 24, 1998
Filed:
Apr 18, 1997
Appl. No.:
8/844024
Inventors:
Aaron E. Katz - Armonk NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C12Q 168, C07H 2104, C12P 1934
US Classification:
435 6
Abstract:
This invention provides a method of determining the stage of prostate cancer in a human subject using a sample of peripheral blood from a human subject. The invention uses reverse transcriptase-PCR to detect the mRNA encoding prostate specific antigen (PSA) in circulating cells expressing PSA. The invention further uses digoxigenin enhancement of the resultant cDNA signal. The method has an overall sensitivity capable of detecting one PSA expressing cell per 100,000 cells. The method produced no false positives and had a superior detection selectivity for patients with nonlocalized prostate cancer.